{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T03:20:14Z","timestamp":1778037614419,"version":"3.51.4"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T00:00:00Z","timestamp":1609632000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T00:00:00Z","timestamp":1609632000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"crossref","award":["JP19mk0101083"],"award-info":[{"award-number":["JP19mk0101083"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"crossref","award":["JP19mk0101083"],"award-info":[{"award-number":["JP19mk0101083"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"crossref","award":["JP19mk0101083"],"award-info":[{"award-number":["JP19mk0101083"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"crossref","award":["JP19mk0101083"],"award-info":[{"award-number":["JP19mk0101083"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ther Innov Regul Sci"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s43441-020-00246-9","type":"journal-article","created":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T18:02:30Z","timestamp":1609696950000},"page":"523-538","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy Comparison for a Schizophrenia and a Dysuria Drug Among East Asian Populations: A Retrospective Analysis Using Multi-regional Clinical Trial Data"],"prefix":"10.1007","volume":"55","author":[{"given":"Kimie","family":"Sai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Nakatani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Iwama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichi","family":"Hiraoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Tohkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Uyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiro","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,3]]},"reference":[{"key":"246_CR1","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/clpt.2013.223","volume":"95","author":"T Ueno","year":"2014","unstructured":"Ueno T, Asahina Y, Tanaka A, Yamada H, Nakamura M, Uyama Y. Significant differences in drug lag in clinical development among various strategies used for regulatory submissions in Japan. Clin Pharmacol Ther. 2014;95:533\u201341.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"246_CR2","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/cts.12485","volume":"10","author":"K Miyazaki","year":"2017","unstructured":"Miyazaki K, Sato Y, Hanaoka H, Uyama Y. Current status and open issues concerning global clinical trials (GCTs) in Japan and East Asia. Clin Transl Sci. 2017;10(6):508\u2013508.","journal-title":"Clin Transl Sci"},{"key":"246_CR3","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/clpt.2009.285","volume":"87","author":"K Ichimaru","year":"2010","unstructured":"Ichimaru K, Toyoshima S, Uyama Y. Effective global drug development strategy for obtaining regulatory approval in Japan in the context of ethnicity-related drug response factors. Clin Pharmacol Ther. 2010;87:362\u20136.","journal-title":"Clin Pharmacol Ther"},{"key":"246_CR4","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1080\/10543406.2012.701581","volume":"22","author":"Y Ando","year":"2012","unstructured":"Ando Y, Uyama Y. Multiregional clinical trials: Japanese perspective on drug development strategy and sample size for Japanese subjects. J Biopharm Stat. 2012;22:977\u201384.","journal-title":"J Biopharm Stat"},{"key":"246_CR5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/clpt.2013.106","volume":"94","author":"K Asano","year":"2013","unstructured":"Asano K, Tanaka A, Sato T, Uyama Y. Regulatory challenges in the review of data from global clinical trials: the PMDA perspective. Clin Pharmacol Ther. 2013;94:195\u20138.","journal-title":"Clin Pharmacol Ther"},{"key":"246_CR6","unstructured":"Ministry of Health, Labour and Welfare of Japan. Basic Principles on Global Clinical Trials (Reference Cases). 2012 [cited 5 September 2012]. https:\/\/www.pmda.go.jp\/files\/000152969.pdf"},{"key":"246_CR7","unstructured":"The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Ethnic factors in the acceptability a foreign clinical data E5 (R1). c1998 [cited 5 February 1998] https:\/\/database.ich.org\/sites\/default\/files\/E5_R1__Guideline.pdf"},{"key":"246_CR8","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/clpt.2008.144","volume":"84","author":"SM Huang","year":"2008","unstructured":"Huang SM, Temple R. Is this the drug or dose for you? Impact and consideration of ethnic factors in global drug development, regulatory review, and clinical practice. Clin Pharmacol Ther. 2008;84:287\u201394.","journal-title":"Clin Pharmacol Ther"},{"key":"246_CR9","unstructured":"The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. General principle on planning\/designing Multi-Regional Clinical Trials. 2017 [cited 16 November 2017]. https:\/\/database.ich.org\/sites\/default\/files\/E17EWG_Step4_2017_1116.pdf"},{"key":"246_CR10","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/sj.clpt.6100482","volume":"84","author":"SP Myrand","year":"2008","unstructured":"Myrand SP, Sekiguchi K, Man MZ, Lin X, Tzeng RY, Teng CH, et al. Pharmacokinetics\/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: Comparison with Korean, Chinese, and Caucasian populations. Clin Pharmacol Ther. 2008;84:347\u201361.","journal-title":"Clin Pharmacol Ther"},{"key":"246_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2133\/dmpk.DMPK-11-RV-111","volume":"27","author":"K Kurose","year":"2012","unstructured":"Kurose K, Sugiyama E, Saito Y. Population differences in major functional polymorphisms of pharmacokinetics\/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development. Drug Metab Pharmacokinet. 2012;27:9\u201354.","journal-title":"Drug Metab Pharmacokinet"},{"key":"246_CR12","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1177\/2168479013517892","volume":"48","author":"M Oishi","year":"2014","unstructured":"Oishi M, Hiro S, Matsuoka N, Hotta S, Ono R, Mori Y, et al. A comparison of the pharmacokinetics and drug safety among East Asian populations. Ther Innov Regul Sci. 2014;48:393\u2013403.","journal-title":"Ther Innov Regul Sci"},{"key":"246_CR13","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1111\/bcp.12884","volume":"81","author":"T Hasunuma","year":"2016","unstructured":"Hasunuma T, Tohkin M, Kaniwa N, Jang IJ, Yimin C, Kaneko M, et al. Absence of ethnic differences in the pharmacokinetics of moxifloxacin, simvastatin, and meloxicam among three East Asian populations and Caucasians. Br J Clin Pharmacol. 2016;81:1078\u20139.","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"246_CR14","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1002\/psp4.12259","volume":"6","author":"T Aoyama","year":"2017","unstructured":"Aoyama T, Ishida Y, Kaneko M, Miyamoto A, Saito Y, Tohkin M, et al. Pharmacokinetics and pharmacodynamics of meloxicam in East Asian populations: The role of ethnicity on drug response. CPT Pharmacometrics Syst Pharmacol. 2017;6(12):823\u201332.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"2","key":"246_CR15","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s10928-017-9556-7","volume":"45","author":"M Kaneko","year":"2018","unstructured":"Kaneko M, Aoyama T, Ishida Y, Miyamoto A, Saito Y, Tohkin M, et al. Lack of ethnic differences of moxifloxacin and metabolite pharmacokinetics in East Asian men. J Pharmacokinet Pharmacodyn. 2018;45(2):199\u2013214.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"6","key":"246_CR16","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1111\/bcp.13893","volume":"85","author":"K Sai","year":"2019","unstructured":"Sai K, Yoshida A, Hanatani T, Imatoh T, Takeuchi M, Narukawa M, et al. Population\/regional differences in efficacy of 3 drug categories (antidiabetic, respiratory and psychotropic agents) among East Asians: A retrospective study based on multiregional clinical trials. Br J Clin Pharmacol. 2019;85(6):1270\u201382.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"246_CR17","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261\u201376.","journal-title":"Schizophr Bull"},{"key":"246_CR18","unstructured":"Guy, W. Clinical Global Impressions. ECDEU assessment manual for psychopharmacology, revised. Rockville, MD: U.S. Department of Health, Education, and Welfare. Public health service, alcohol, drug abuse, and mental health administration; National Institute of Mental Health, psychopharmacology research branch, division of extramural research programs; 1976. p. 218\u2212222."}],"container-title":["Therapeutic Innovation & Regulatory Science"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-020-00246-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s43441-020-00246-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-020-00246-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T15:22:16Z","timestamp":1617636136000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s43441-020-00246-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,3]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["246"],"URL":"https:\/\/doi.org\/10.1007\/s43441-020-00246-9","relation":{},"ISSN":["2168-4790","2168-4804"],"issn-type":[{"value":"2168-4790","type":"print"},{"value":"2168-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,3]]},"assertion":[{"value":"30 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was conducted through collaboration between the project team and pharmaceutical companies. Drs. Sai, Tohkin, Uyama and Saito report grants from AMED (JP19mk0101083) during the conduct of the study. Mr. Iwama and Dr. Hiraoka are employed by Meiji Seika Pharma Co., Ltd. (Tokyo, Japan). Dr. Tohkin reports grants from Grant-in-Aid for Scientific Research (C), grants from Food Safety Commission, grants from AI-SHIPS project, outside the submitted work; No other conflicting interests exist.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by all collaborating companies and the ethics committee of NIHS (NIHS approval No.\u00a0295-2).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}